View Older Stories View More Recent Stories

Oct 3, 2023 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 6, 2023 08:00AM Astria Therapeutics to Participate in Upcoming Investor Conferences
Aug 31, 2023 08:01AM Astria Therapeutics, Inc. (ATXS) Announces Publication of STAR-0215 Preclinical Data
Aug 31, 2023 08:00AM Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
Aug 25, 2023 08:00AM Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
Aug 7, 2023 04:10PM Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
Aug 2, 2023 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Jul 20, 2023 08:01AM Astria Therapeutics (ATXS) Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
Jul 20, 2023 08:00AM Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
Jul 17, 2023 08:00AM Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations
Jul 14, 2023 08:00AM Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
Jul 6, 2023 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2023 08:00AM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 5, 2023 08:00AM Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting
May 31, 2023 08:00AM Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
May 11, 2023 04:10PM Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
May 2, 2023 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 28, 2023 08:00AM Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop
Apr 19, 2023 08:02AM Astria Therapeutics (ATXS) Appoints Andrea Matthews as Chief Business Officer
Apr 19, 2023 08:00AM Astria Therapeutics Names Andrea Matthews Chief Business Officer
Apr 4, 2023 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 22, 2023 08:00AM Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Mar 8, 2023 08:00AM Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
Mar 6, 2023 08:00AM Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
Mar 2, 2023 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 24, 2023 08:00AM Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunolog
Feb 21, 2023 08:00AM Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
Feb 8, 2023 08:00AM Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
Feb 2, 2023 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 2, 2022 04:00PM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 10, 2022 04:10PM Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Nov 9, 2022 08:00AM Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
Nov 7, 2022 08:00AM Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
Nov 2, 2022 08:00AM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 16, 2022 08:00AM Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
Sep 6, 2022 08:00AM Astria Therapeutics to Present at Upcoming Investment Conferences
Sep 2, 2022 08:00AM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 9, 2022 04:32PM Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Aug 4, 2022 08:00AM Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
Aug 3, 2022 08:00AM Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
Aug 2, 2022 08:00AM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 28, 2022 08:00AM Astria Therapeutics (ATXS) Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
Jul 28, 2022 08:00AM Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
Jul 15, 2022 08:02AM Astria Therapeutics, Inc. (ATXS) Appoints Chris Morabito as Chief Medical Officer
Jul 15, 2022 08:00AM Astria Therapeutics Names Chris Morabito Chief Medical Officer
Jul 14, 2022 08:00AM Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference
Jul 5, 2022 08:00AM Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema
Jun 23, 2022 08:00AM Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress
Jun 3, 2022 08:00AM Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
Jun 2, 2022 08:00AM Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories